Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SL-T10, GX-I7 and Pembrolizumab in mCRPC
NCT06344715Phase 1Recruiting
- Start
- Oct 2022
- Primary completion
- Oct 2024
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of SL-T10 in metastatic castration-resistant prostate cancer (mCRPC) (6 cohorts). Primary endpoints: Number of participants with treatment-emergent adverse events at 23 weeks and Number of participants with Serious adverse events at 48 weeks. Started Oct 2022; status: recruiting.
02
Drugs
SL-T10
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06344715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06344715.